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Summary
 
The Wiskott-Aldrich syndrome protein (WASp) has been implicated in modulation of lym-
phocyte activation and cytoskeletal reorganization. To address the mechanisms whereby WASp
subserves such functions, we have examined WASp roles in lymphocyte development and acti-
vation using mice carrying a 
 
WAS
 
 null allele (
 
WAS
 
2
 
/
 
2
 
). Enumeration of hemopoietic cells in
these animals revealed total numbers of thymocytes, peripheral B and T lymphocytes, and
platelets to be significantly diminished relative to wild-type mice. In the thymus, this abnor-
mality was associated with impaired progression from the CD44
 
2
 
CD25
 
1
 
 to the CD44
 
2
 
CD25
 
2
 
stage of differentiation. WASp-deficient thymocytes and T cells also exhibited impaired prolif-
eration and interleukin (IL)-2 production in response to T cell antigen receptor (TCR) stimu-
lation, but proliferated normally in response to phorbol ester/ionomycin. This defect in TCR
signaling was associated with a reduction in TCR-evoked upregulation of the early activation
marker CD69 and in TCR-triggered apoptosis. While induction of TCR-
 
z
 
, ZAP70, and total
protein tyrosine phosphorylation as well as mitogen-activated protein kinase (MAPK) and stress-
activated protein/c-Jun NH
 
2
 
-terminal kinase (SAPK/JNK) activation appeared normal in
TCR-stimulated 
 
WAS
 
2
 
/
 
2
 
 cells, TCR-evoked increases in intracellular calcium concentration
were decreased in WASp-deficient relative to wild-type cells. 
 
WAS
 
2
 
/
 
2
 
 lymphocytes also man-
ifested a marked reduction in actin polymerization and both antigen receptor capping and
endocytosis after TCR stimulation, whereas 
 
WAS
 
2
 
/
 
2
 
 neutrophils exhibited reduced phagocytic
activity. Together, these results provide evidence of roles for WASp in driving lymphocyte de-
velopment, as well as in the translation of antigen receptor stimulation to proliferative or apop-
totic responses, cytokine production, and cytoskeletal rearrangement. The data also reveal a role
for WASp in modulating endocytosis and phagocytosis and, accordingly, suggest that the immune
deficit conferred by WASp deficiency reflects the disruption of a broad range of cellular behaviors.
Key words: immunodeﬁciency • Wiskott-Aldrich syndrome protein • antigen receptor 
signaling • cytoskeletal rearrangement • lymphocyte activation
 
T
 
he Wiskott-Aldrich syndrome (WAS)
 
1
 
 is an X-linked
immune deficiency syndrome classically characterized
by the triad of eczema, impaired cellular and humoral im-
munity, and thrombocytopenia (1, 2). A multiplicity of
hemopoietic cell defects have been described among the
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affected boys, but the most characteristic include impair-
ment in T cell functions such as delayed hypersensitivity
and response to allogeneic and mitogenic stimuli, as well as
a marked reduction in platelet number, size, and response
to agonist stimulation (3–8). These abnormalities have, in
turn, been shown to be associated with a spectrum of bio-
chemical defects, most notably including impaired trans-
duction of early activation signals through the antigen re-
ceptors on B and T lymphocytes and through the thrombin
receptors on platelets (8–12). In addition, WAS patient
lymphocytes and platelets manifest cytoskeletal abnormali-
ties, as evidenced in lymphocytes by reduced numbers of
surface microvilli projections and an aberrant pattern of ac-
tin reorganization after cell stimulation (12, 13); in platelets
by altered cell size, shape, and filamentous (F)-actin content
(5, 11); and in monocytes by decreased chemotaxis and lack
of polarization in response to chemoattractants (14, 15). In
view of these observations, WAS has long been considered
to reflect the sequela of a protein deficit that disrupts signal-
ing pathways coupling extracellular stimuli to both cyto-
skeletal rearrangement and nuclear response. Data from
X-inactivation studies have revealed the WAS defect to be
expressed early in hemopoietic ontogeny (16, 17), and this
finding, together with the immunophenotypic characteris-
tics of WAS lymphocytes (18), the functional similarities
between WAS B cells and neonatal, immature B cells (19),
and the altered 
 
O
 
-glycosylation profile observed in WAS
lymphocyte glycoproteins (20–22), suggest that the WAS
phenotype reflects impaired lymphocyte maturation as well
as activation and structure.
The product of the WAS gene, WASp, has now been
identified (23), and available data concerning the structural
and biochemical properties of this cytosolic, hematopoie-
tic-restricted protein are consistent with the hypothesized
role for WASp in the regulation of cellular activation and
cytoskeletal arrangement (23–25). For example, the protein
contains COOH-terminally located regions of homology
with the cytoskeletal proteins cofilin and verprolin (26, 27)
as well as a cdc42/Rac interactive binding motif that has
been shown to mediate WASp binding to the activated
form of cdc42 (28). This latter Rho family GTPase has
been implicated in the actin reorganization induced by fibro-
blast stimulation (29) and also in the polarization of the T
cell cytoskeleton towards APCs (30). WASp has also been
shown to colocalize with actin in T cells and megakaryo-
cytes (31) and to be required for actin remodeling in some
hemopoietic lineages (32). Similarly, the yeast WASp homo-
logue, LAS17/Bee1, has been implicated in assembly of the
cortical actin cytoskeleton (33); the WASp homologue,
N-WASp, has been shown to participate in actin depoly-
merization and filopodium formation (34); and the WASp-
related WASp family Verprolin homologous (WAVE) pro-
tein appears to be required for the coupling of Rac to actin
rearrangements involved in membrane ruffling (35). These
observations, together with data demonstrating that sup-
pressor of cAR (SCAR1), another WASp family protein, as
well as WASp itself interact with the actin-related protein
(Arp2/3) complex and are involved in formation of plate-
let-derived growth factor–induced lamellipodia (36, 37),
indicate a pivotal role for WASp in regulating actin organi-
zation and the cytoskeletal rearrangements induced by exter-
nal stimuli.
In addition to its interactions with cdc42 and cytoskeletal
components, WASp also contains a putative pleckstrin ho-
mology domain at its NH
 
2
 
 terminus (38) and a proline-rich
region which has been shown to interact with Nck, Fyn,
and several other Src homology 3 (SH3) domain–contain-
ing proteins implicated in intracellular activation cascades
(39–44). These properties of WASp suggest that the func-
tions subserved by this protein include not only cytoskele-
tal modification, but also intracellular transduction of acti-
vating signals. This latter contention is consistent with data
demonstrating that antigen receptor–induced proliferation
is impaired in WAS patients (9, 10) as well as in WASp-
deficient mice (45). At present, however, the mechanisms
whereby WASp influences cell activation and structural ar-
rangement are poorly understood. In this context, we have
derived mice carrying a 
 
WAS
 
 null allele and examined the
effects of WASp deficiency on lymphocyte development
and response to antigen receptor stimulation. Analyses of
these 
 
WAS
 
2
 
/
 
2
 
 animals has provided definitive evidence of a
critical role for WASp in coupling antigen receptor en-
gagement to both receptor capping and endocytosis and to
the signaling cascades that evoke proliferation, IL-2 produc-
tion, and apoptosis. The data also reveal an important role
for WASp in driving the development/expansion of ma-
ture peripheral T and B cells and in promoting the progres-
sion of immature thymocytes from the double-negative to
the CD4
 
1
 
CD8
 
1
 
 double-positive stage. However, investi-
gation of the signaling pathways downstream of TCR en-
gagement indicate that early activation events such as tyro-
sine phosphorylation of ZAP70, TCR-
 
z
 
, and other cellular
proteins, as well as activation of the mitogen-activated pro-
tein kinase (MAPK) and the stress-activated protein/c-Jun
NH
 
2
 
-terminal kinase (SAPK/JNK), are unaffected by WASp
deficiency. Together, these observations identify WASp as
a regulator of lymphocyte ontogeny, cytoskeletal structure,
and activation and suggest that WASp effects on lympho-
cyte behavior are realized through modulation of the cyto-
skeletal processes governing antigen receptor rearrangement
and terminal activation events such as proliferation and cy-
tokine production.
 
Materials and Methods
 
Reagents.
 
Antibodies used for these studies included the follow-
ing: FITC-conjugated Ly9.1, anti–Thy 1.2, anti-CD8, anti-Fas,
anti-IgM, anti-CD4, anti-CD5, and anti-IgD; PE-conjugated anti-
CD4, anti-CD3
 
e
 
, anti-CD44, anti-CD43, anti-CD23, and anti–
IL-2 and anti-B220; biotin-conjugated anti–TCR-
 
a
 
/
 
b
 
, anti-IgD,
anti-CD19, and anti-CD25; allophycocyanin-conjugated anti–
TCR-
 
a
 
/
 
b
 
, anti-CD3, anti-CD4, anti-CD8, anti-B220, anti-CD40,
and anti-IgM antibodies and Cy5-conjugated streptavidin, all from
PharMingen; and anti–extracellular signal regulatory kinase (ERK)1
and anti-ERK2 antibodies from Santa Cruz, anti–TCR-
 
z
 
 and
anti-ZAP70 antibodies supplied by Drs. Larry Samelson (National
Institutes of Health, Bethesda, MD) and André Veillette (McGill 
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Cancer Centre, Montreal, Quebec, Canada), respectively; and
antiphospho-SAPK/JNK and anti-SAPK/JNK antibodies (reac-
tive against all SAPK/JNK isoforms) from New England Biolabs.
Texas red–conjugated streptavidin was purchased from GIBCO
BRL. Monoclonal hamster anti–mouse CD3
 
e
 
 was produced by
the 145-2C11 hybridoma (provided by Dr. R. Miller, Ontario
Cancer Institute) and purified from the supernatant by protein G
chromatography; polyclonal rabbit anti-WASp antibody was de-
rived by immunization with a polylysine-conjugated peptide cor-
responding to a putative nuclear localization signal within the 
 
WAS
 
cDNA; anti–murine 
 
b
 
-actin mAb, PMA, ionomycin, and murine
recombinant IL-2 were purchased from Sigma Chemical Co.;
rabbit anti–hamster and anti–mouse IgG antibodies and FITC-
conjugated streptavidin were purchased from Jackson Immuno-
Research Laboratories. Murine recombinant IL-4 was obtained
from PharMingen, [
 
3
 
H]thymidine from Dupont/NEN, 7-amino-
actinomycin D (7-AAD) from Calbiochem, Indo-1 from Molec-
ular Probes, myelin basic protein (MBP) from Upstate Biotech-
nology, Inc., and an IL-2 ELISA kit from Genzyme. Brefeldin A
was a gift from Dr. R. Miller.
 
Generation of WASp-deficient Mice.
 
A 
 
WAS
 
 gene targeting
vector was derived by subcloning a 3.3-kb segment of the 
 
WAS
 
gene encompassing 
 
z
 
2 kb of the 5
 
9
 
 flanking sequence upstream
of the initiation codon through exon 4 of the gene into the
Ssc8387I site of the pPNT expression cassette (46) and a 3.4-kb
fragment encompassing the XbaI site in exon 11 through to a
BamHI site within intron 11 into the pPNT XbaI-BamHI sites.
Embryonic stem (ES) cells from the male-derived R1 ES cell line
(129/Sv) were electroporated with this targeting vector and se-
lected with neomycin and gancyclovir (47). Surviving clones were
screened for homologous recombination at the 
 
WAS
 
 locus by
PCR using the following primer pair: 5
 
9
 
-GTGAAGGATAA-
CCCTCAGAAGTCC-3
 
9
 
 (forward primer, S1, derived from
sequences within exon 2 of the 
 
WAS
 
 gene) and 5
 
9
 
-CGGAGCA-
GAATCTAGATGGCAGAGT-3
 
9
 
 (reverse primer, S2, represent-
ing sequences in the 3
 
9
 
 region downstream from exon 12 of the
 
WAS
 
 gene) (see Fig. 1 A). Targeted clones were verified by
Southern blotting with a probe derived from a 450-bp segment
external to the 5
 
9
 
 region of homology (see Fig. 1 B). Two inde-
pendently derived 
 
WAS
 
2
 
/
 
2
 
 clones were then either aggregated
with CD1 eight cell stage embryos or microinjected into 3.5-d
recombinase activating gene 2–deficient (
 
RAG-2
 
2
 
/
 
2
 
) blastocysts
(48), and the aggregates or blastocysts were then implanted into
pseudopregnant foster mothers.
 
WAS
 
 genotypes of the chimeric progeny were confirmed us-
ing a PCR assay including the forward primer (G1; 5
 
9
 
-ACTG-
AAGGCTCTTTACTATTGCT-3
 
9
 
), derived from a sequence
within the neomycin resistance gene, and a reverse primer (G2;
5
 
9
 
-ACTGAAGCCTCTTTACTATTGCT-3
 
9
 
), corresponding to
a sequence within exon 11 of the 
 
WAS
 
 gene. Chimeric male
mice carrying the mutation in the germline were bred to the
C57BL/6 background by backcrossing over six generations.
 
Flow Cytometry Analysis.
 
Cells were resuspended in immu-
nofluorescence staining buffer (PBS containing 1% BSA and 0.05%
NaN
 
3
 
) and incubated with the appropriate fluorochrome-conju-
gated antibodies for 30 min at 4
 
8
 
C. For three- and four-color
staining, Texas red– or Cy5-conjugated streptavidin was used af-
ter staining with biotin-conjugated antibodies. Stained cells were
analyzed using a FACScan™ with CELLQuest™ software (Bec-
ton Dickinson). For detection of expression of the early activa-
tion marker CD69, thymocytes (2 
 
3 
 
10
 
6
 
 cells/ml) were cultured
with medium alone, with plate-bound anti-CD3 antibody (10
 
m
 
g/ml), or with plate-bound anti-CD3 plus anti-CD28 antibod-
ies (10 and 0.2 
 
m
 
g/ml, respectively) for 24 h. Cells were stained
with FITC-conjugated anti-CD8, PE-conjugated anti-CD4, and
biotinylated anti-CD69 antibodies followed by Cy5-conjugated
streptavidin. Expression of CD69 was measured on gated CD4
 
1
 
CD8
 
1
 
 thymocytes.
 
Cell Stimulation.
 
For analysis of cell proliferation, single cell
suspensions were prepared from thymi, lymph nodes, and spleen
of age-matched 
 
WAS
 
2
 
/
 
2
 
 and 
 
WAS
 
1
 
/
 
1
 
 (C57BL/6) mice bred at
the Samuel Lunenfeld Research Institute, and the cells were then
subjected to erythrocyte lysis in ammonium chloride buffer. Thy-
mocytes and lymph node cells were cultured in 96-well flat-bot-
tomed microtiter plates (2 
 
3
 
 10
 
6
 
 cells/ml) for 48 h in culture me-
dium alone or in the presence of either plate-bound (0–25 
 
m
 
g/ml)
or soluble (2 
 
m
 
g/ml) anti-CD3
 
e
 
 antibody with or without anti-
CD28 antibody (0.2 
 
m
 
g/ml) or with soluble anti-CD3 antibody
plus PMA (1 
 
m
 
g/ml and 5 ng/ml, respectively), Con A (1 
 
m
 
g/ml)
or PMA plus ionomycin (5 
 
m
 
g/ml and 250 ng/ml, respectively),
or soluble anti-CD3 antibody plus IL-2 (1 
 
m
 
g/ml and 50 U/ml,
respectively). Splenocytes (2 
 
3 106 cells/ml) were cultured for 48 h
with medium alone, LPS (5 mg/ml), IL-4 (2 ng/ml), or IL-4
plus anti-IgM antibody F(ab9)2 fragment (1.25 and 5 mg/ml), or
anti-CD40 antibody (2 mg/ml). Cultured cells were pulsed with
[3H]thymidine (1 mCi/well) for 16 h before terminating the incu-
bation. Incorporated radioactivity was measured using an auto-
mated b scintillation counter. Alternatively, for biochemical assays,
4 3 107 thymocytes or lymph node T cells were resuspended in
100 ml 2% FCS–containing RPMI and incubated for 30 min at
48C in the presence or absence of biotin-conjugated anti-CD3
antibody (25 mg/ml). After removal of unbound antibody, the
cells were resuspended at a concentration of 2 3 108 cells/ml,
warmed to 378C for 1 min, and incubated for varying periods
with 10 mg/ml streptavidin.
Evaluation of IL-2 Production. To evaluate IL-2 secretion, su-
pernatants were collected from unstimulated and TCR-stimu-
lated cells and the amount of IL-2 was quantified by ELISA
(Genzyme). Numbers of IL-2–producing cells were assayed by
incubating stimulated and unstimulated lymph node T cells (2 3
106) in 24-well plates precoated with anti-CD3 antibody (5 mg/ml)
with or without addition of soluble anti-CD28 antibody (4 mg/ml)
and in the presence or absence of Brefeldin A (5 mM) at 378C for
8 h. Cells were harvested, washed with immunofluorescence
buffer, and labeled with an FITC-conjugated anti-CD4 antibody.
Cells were then washed again and incubated for 15 min in 150 ml
of 4% paraformaldehyde at room temperature. Cells were then
washed, permeabilized, and labeled by 2-h incubation with a PE-
conjugated anti–IL-2 antibody in 100 ml of 0.1% saponin–con-
taining immunofluorescence buffer. Cells were washed twice with
permeabilization buffer, resuspended in immunofluorescence
buffer, and analyzed by flow cytometry.
Immunoblotting, Immunoprecipitation, and MAPK Assay. Spleno-
cytes and thymocytes (2 3 106 cells) from WAS1/1 and WAS2/2
mice were lysed in buffer containing 50 mM Tris, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 1 mM PMSF, and 1 mg/ml each of leu-
peptin, pepstatin, and aprotinin as protease inhibitors. After 15
min incubation in cold lysis buffer, unlysed cells were removed
by centrifugation and the lysates were then boiled in the presence
of 63 reducing sample buffer, electrophoresed through 10%
SDS-polyacrylamide, and transferred to nitrocellulose (Schleicher &
Schuell). The filters were incubated at 48C for at least 1 h in
TBST solution (150 mM NaCl, 10 mM Tris-HCl, pH 7.4,
0.05% Tween 20) plus 3% gelatin. Filters were then incubated for
2 h at room temperature with anti-WASp antibody (1 mg/ml) in
TBST, followed by the addition of goat anti–mouse antiserum la-1332 Regulation of Lymphocyte Function by the Wiskott-Aldrich Syndrome Protein
beled with peroxidase (Amersham Pharmacia Biotech) and horse-
radish peroxidase conjugate (Bio-Rad Laboratories). The blot was
stripped and reprobed with an anti–b-actin antibody in order to
assess loading. For immunoprecipitation, lysates prepared from
unstimulated or TCR-stimulated thymocytes or lymph node T
cells (4 3 107) were precleared by incubating an equal amount
(100–250 mg) lysate protein with protein A–Sepharose (Amer-
sham Pharmacia Biotech) for 1 h at 48C and for an additional 1 h
with 40 ml rabbit preimmune sera. Lysates were then incubated
for 3 h at 48C with specific antibody or rabbit preimmune serum
and 25 ml packed protein A–Sepharose beads, and the immune
complexes were then collected by centrifugation, washed four
times in lysis buffer, and resuspended in SDS sample buffer for
immunoblotting analyses. Alternatively, ERK1/ERK2 immune
complexes immunoprecipitated using a mixture of anti-ERK1
and anti-ERK2 antibodies were washed in MAPK buffer (5 mM
Hepes, pH 7.4, 10 mM MgCl2, 100 mM NaVO4) and resus-
pended in 50 ml reaction buffer (30 mM Tris-HCl, pH 8.0, 20
mM MgCl2, 2 mM MnCl2 containing 5 mg MBP [Upstate Bio-
technology], 1 mM cold ATP, and 10 mCi [g-32P]ATP [Dupont/
NEN]). After 15 min incubation at 308C, reactions were termi-
nated by addition of 12 ml 63 SDS-PAGE loading buffer, and
the samples were boiled, electrophoresed through 12% polyacryl-
amide gels, and transferred to nitrocellulose. The phosphorylated
MBP bands were visualized by autoradiography, and ERK1 and
ERK2 expression levels were determined by anti-ERK2 immu-
noblotting analysis.
Measurement of Ca21 Influx. Thymocytes and lymph node T
cells (5 3 106 cells/ml) were labeled with Indo-1 (5 mM) and in-
cubated at 378C in the dark for 30 min. Cells were washed, resus-
pended in RPMI containing 2% FBS and 10 mM Hepes, pH 7.4,
and incubated with biotinylated anti-TCR antibody (5 mg/ml)
for 15 min at 48C. After washing, the cells were resuspended
in RPMI buffer at a concentration of 107 cells/ml and stimulated
with 5 mg/ml of streptavidin. Calcium levels were detected by flow
cytometric analysis of Indo-1 violet-blue fluorescence ratio (49).
Induction of Apoptosis. Freshly isolated thymocytes were plated
at a density of 2 3 106 cells/ml in 96-well tissue culture plates
precoated with either anti-CD3 antibody (20 mg/well), anti-CD3
plus anti-CD28 (each 20 mg/well), anti-Fas antibody (0.1, 1, or
5 mg/ml), or PMA plus ionomycin (10 and 500 ng/ml, respec-
tively). After 24 h, the cells were harvested, washed with PBS, and
stained with FITC-conjugated anti-CD4, PE-conjugated anti-
CD8, and 7-AAD (10 mg/ml) for 30 min on ice (50). After three
washes, the cells were analyzed using the Becton Dickinson
FACScan™ and CELLQuest™ software.
Capping and Endocytosis of T and B Cell Antigen Receptors. 106
cells were incubated with 1 mg/ml of biotinylated anti-TCR
(thymus) or 1 mg/ml of biotinylated anti–mouse IgD (spleen), for
30 min on ice. After washing, cells were labeled for 30 min on
ice with 1 mg/ml streptavidin-FITC. Cells were washed and re-
suspended in 100 ml of RPMI and incubated at 378C for 5 min.
The cells were pelleted in a microcentrifuge for 15 s and then
fixed for 15 min in 2% paraformaldehyde. After washing twice in
0.5% BSA–containing PBS, the cells were cytospun onto slides
and mounted with SlowFade Light (Molecular Probes). The cells
were visualized with a confocal fluorescence microscope (MRC-
600; Bio-Rad Laboratories). The average percentage of capped
cells was obtained from 10 microscope fields per sample (100–
200 cells/field).
Internalization of the TCR was assayed by incubating 106
lymph node T cells with anti-CD3 antibody (1 mg/ml) for 30 min
on ice. After washing, cells were incubated with biotinylated goat
anti–hamster antibody (2 mg/ml) for 30 min at 48C and then
warmed at 378C. Aliquots were removed at varying time points
thereafter, transferred to ice, and the reaction was stopped by ad-
dition of 0.1% NaN3. Cells were then stained with FITC-conju-
gated streptavidin, fixed for 15 min in 4% paraformaldehyde, and
washed before analysis by flow cytometry.
Actin Polymerization Assay. Thymocytes were incubated with
anti-CD3e (1 mg/ml) for 30 min on ice. After washing, the primary
antibodies were cross-linked using goat anti–hamster Ig (1 mg/ml)
for 5 min. The control cells were incubated only with the cross-
linking antibody. Activation was terminated by addition of 4%
paraformaldehyde. After fixation, cells were incubated with
FITC-conjugated phalloidin (Sigma Chemical Co.) for 30 min,
washed three times in PBS, and analyzed using a FACSCalibur™.
Phagocytosis. Long bones (humerus, femur, tibia) were re-
moved from selected mice, and the ends were then clipped and
flushed using a 27-gauge needle and ice-cold HBSS. Clumps of
marrow were then broken up by repeated pipetting, and the cells
were spun at 500 g at 48C for 5 min, resuspended in HBSS in a
15-ml polypropylene tube, and underlaid with a discontinuous
Percoll gradient (52, 65, and 75% Percoll solution). Cells were
then centrifuged at 1,500 g for 30 min at 48C, and the neutrophil-
enriched fraction (at the interface of the 65 and 75% gradients)
was harvested, diluted with an equal volume of HBSS, and spun
down in a microfuge for 10 s. These cells were resuspended in 1 ml
of RPMI and counted using a Coulter counter. To evaluate pha-
gocytosis, cells were mixed with opsonized zymosan (10 parti-
cles/cell) and lucifer yellow at 0.5 mg/ml, pelleted in a microfuge
tube, and then incubated for 5 min at 378C. Cells were then
washed three times in ice-cold PBS, and the number of cells with
lucifer yellow–containing phagosomes was counted using a fluo-
rescence microscope.
Results and Discussion
WASp Deficiency Engenders a Defect in Lymphoid Ontogeny.
To derive ES cells carrying a disruption of the WAS gene,
a targeting construct was developed in which a 3.5-kb seg-
ment encompassing intron 4 to exon 11 of the WAS gene
was substituted with the pPNT expression vector. This vec-
tor was then introduced into R1 ES cells, and two clones
carrying a WAS mutant allele were then aggregated with
CD1 eight cell embryos. Once germline transmission of
the targeted allele was confirmed by PCR and Southern
analysis (Fig. 1, A and B), the WAS mutation was bred into
the C57BL/6 background. The two WAS2/2 ES cell clones
were also injected into RAG2/2 blastocysts so as to derive
WAS2/2RAG2/2 chimeric mice which were used in addi-
tion to the WAS2/2 mice for some studies of lymphocyte
function. As illustrated by immunoblotting analysis, male
mice carrying the WAS mutant allele showed no WASp
expression in either thymic or splenic cells (Fig. 1 C) despite
the presence of surface (s)Ig1 B cells and mature CD41
CD82 and CD42CD81 T cells (Fig. 1 D).
Although lymphoid cells were present in the WAS2/2
mice, an analysis of cell numbers in these animals revealed
lymphocyte cellularity to be reduced in all lymphoid organs
examined. A reduction in lymphoid cell number was most
evident in the thymus, where the number of thymocytes
was about one quarter of that observed in wild-type mice1333 Zhang et al.
(Table I). Reduced thymic cellularity appeared to reflect a
decrease in the total and relative numbers of CD41CD81
double-positive thymocytes, an abnormality which, in turn,
was associated with relative increases in the numbers of
double-negative CD42CD82 and single-positive CD41
CD82 and CD42CD81 cells (Fig. 1 D). Although this de-
fect was not detected in a previous analysis of WASp-defi-
cient mice (45), the current findings are consistent with
several lines of evidence revealing lymphocyte maturation
to be altered in WAS patients (17, 18, 22). To further
examine this maturation defect, the CD42CD82 double-
negative precursors, identified by virtue of negative staining
for CD4, CD8, B220, TCR-a/b, and TCR-g/d, were
evaluated for expression of the maturation markers CD25
and CD44. These latter markers have been previously
shown to identify four double-negative thymocyte subsets,
CD441CD252, CD441CD251, CD442CD251, and CD442
CD252, which demarcate progressive stages of thymocyte
maturation (51). As shown in Fig. 1 D (lower panel), among
these four double-negative subsets, the CD442CD251 pop-
ulation was relatively increased and the CD442CD252
population relatively decreased in the WAS2/2 compared
with wild-type mice. Thus the reduction in total thymo-
cyte numbers observed in the absence of WASp appears to
reflect impaired progression of the CD442CD251 to the
CD442CD252 stage and by extension, reduced transit from
the double-negative to the double-positive stage. Interest-
Figure 1. Characterization of WAS genotypes and thymocyte popula-
tions in WAS2/2 mice. (A) Long-range PCR genotyping used in screen-
ing the ES clones. The wild-type (1/1) allele appears as an 8-kb fragment,
and the mutant (2/2) allele appears as a 6.3-kb fragment. A molecular
mass standard (1-kb ladder) is shown on the left. (B) Southern blot analy-
sis for detection of targeted clones. BamHI-digested DNA from the re-
spective clones was electrophoresed through 0.8% agarose, transferred to
nitrocellulose, and the filters were hybridized with a 450-bp segment
from the 59 flanking region of the WAS gene. The 10.5-kb fragment rep-
resents hybridization to homologously targeted alleles, and the 6.5-kb
band represents hybridization to the wild-type allele. (C) Spleen and thy-
mus from WAS2/2 mice are null for the expression of WASp. Splenocyte
and thymocyte lysates from control (1/1) and WAS2/2 mice were ana-
lyzed by Western blotting as described in Materials and Methods. The
blot was probed with an anti-WASp polyclonal antibody (top panel).
Equal loading was assessed by reprobing the blot with an anti–b-actin an-
tibody (bottom panel). (D) Immunofluorescence analysis of T and B cell
development in WAS2/2 mice. Thymocytes and lymph node T cells from
4–8-wk-old WAS2/2 and age-matched control (1/1) mice were assayed
for CD4 and CD8 expression (top and middle panels) or expression of
CD25 and CD44 (bottom panel). To analyze the early stages of thymic
development, four-color staining of thymocytes was carried out by stain-
ing the cells with a cocktail containing allophycocyanin-labeled anti-CD3, anti-CD4, anti-CD8, anti–TCR-a/b, and anti-B220 antibodies, and subse-
quently with FITC-Ly9.1, biotinylated anti-CD25 (detected with Texas red–conjugated streptavidin), and PE-labeled anti-CD44. Fluorescence signals
were evaluated using Becton Dickson FACScan™ and CELLQuest™ software and were gated to display CD25 versus CD44 on Ly-9.11 (ES-derived)
CD4, CD8, CD3 triple-negative cells (bottom panel). Numbers in the quadrants indicate percentages of different cell populations, while numbers below
each panel indicate total number of thymic cells. Data shown are representative of four independent experiments.
Table I. Cell Numbers in WAS2/2 Mice
Tissue
Total no. of cells (31026) 6 SD
1/1 WAS2/2
Thymus 116.0 6 16.6 43.6 6 12.5
Lymph nodes 49.3 6 10.0 24.8 6 2.7
Spleen 47.0 6 7.8 20.4 6 2.8
Bone marrow 10.3 6 1.4 10.0 6 2.6
Platelets 616.0 6 65.4 377.8 6 94.2
Total thymocytes, total mesenteric, axillary and inguinal lymph node T
cells, total splenocytes, and bone marrow cells (one femur) from wild-
type (1/1; n 5 4) and WAS2/2 (n 5 4) mice were isolated and
counted; blood platelet count (cells/ml) was determined from tail-bled
wild-type and WAS2/2 mice (n 5 5).1334 Regulation of Lymphocyte Function by the Wiskott-Aldrich Syndrome Protein
ingly, this same perturbance in thymocyte maturation has
also been detected in animals deficient for the CD45 (52),
Lck (53), and Vav (54, 55) signaling effectors, an observa-
tion which strongly suggests that this defect reflects dimin-
ished signaling, most likely via the pre-TCR (56).
WAS2/2 thymocytes were also examined for expression of
TCR-a/b, CD3, and the maturation marker CD5, all of
which were found to be expressed normally on the mutant
thymocytes (data not shown). Similarly, analysis of splenic
and bone marrow B cell populations revealed expression of
CD43, CD19, CD23, CD86, CD25, B220, sIgM, and sIgD
to be comparable in WAS2/2 and wild-type mice (data not
shown). However, for thymocytes, total numbers of periph-
eral CD41CD82 and CD42CD81 T cells and peripheral
B2201sIgM1 B cells were reduced by z50% in the WAS2/2
chimeric compared with wild-type animals (Table I). To-
gether, these data indicate lymphopoiesis to be impaired, al-
beit not arrested, in the context of WASp deficiency. WASp
effects on lymphoid ontogeny appear to be predominantly re-
alized in the thymic compartment at the double-negative
stage of thymocyte differentiation, and it may be for this rea-
son, as well as sensitivity of this defect to strain background
(54), that impaired thymic ontogeny was not detected in an
independently derived WAS2/2 mouse (45). Importantly,
however, in the latter mice, as well as in some WAS patients
(6), significant reductions of peripheral T lymphocyte num-
ber have been observed. Thus, the available evidence strongly
suggests a role for WASp in driving the maturation and/or
expansion of T and possibly mature B cell populations.
Whether this latter role is subserved by WASp modulation of
the proliferation/expansion and/or survival of lymphoid pre-
cursors remains to be determined. Alternatively, the reduc-
tion in lymphocyte number observed in the WAS2/2 mice
might reflect perturbation in the transit of immature precur-
sors from the bone marrow to other lymphoid organs.
In addition to lymphocytes, platelets were also found to
be reduced in the periphery of WAS2/2 mice. As shown in
Table I and consistent with the detection of thrombo-
cytopenia in virtually all WAS patients, platelet number was
reduced by z40% in the WAS2/2 relative to wild-type
mice. At present, the basis for this finding remains unclear,
with preliminary data revealing that platelet survival is nor-
mal in these animals (data not shown). The physiologic sig-
nificance of this defect is also unclear, as the WAS2/2 mice,
in contrast to classical WAS patients, show no overt signs of
a hemorrhagic diathesis.
Antigen Receptor–induced Activation Is Impaired in WASp-
deficient Lymphocytes. In view of previous data suggesting
that antigen receptor–evoked lymphocyte activation is im-
paired in WAS patients (9, 10, 12), thymocytes and periph-
eral B and T lymphocytes from the WAS2/2 chimeras were
next studied with respect to their responses to antigen re-
ceptor ligation. The results of these analyses revealed that
anti-CD3 antibody–evoked proliferation was markedly
reduced in WAS2/2 relative to WAS1/1 thymocytes (Fig.
2 A) at all anti-CD3 antibody concentrations tested (data not
shown). Similarly, Con A stimulation elicited significantly
less proliferation in WAS2/2 thymocytes than wild-type
cells. By contrast, the mutant cells proliferated normally in
response to PMA and ionomycin, a maneuver which trig-
gers proliferation in the absence of antigen receptor en-
gagement. In addition, anti-CD3 as well as anti-CD3 plus
anti-CD28 antibody–induced upregulation of the CD69
early activation marker (57, 58) were markedly diminished
in the mutant cells (Fig. 2 D).
Similar to WAS2/2 thymocytes, WASp-deficient periph-
eral T cells were also observed to have reduced prolifera-
tive responses to anti-CD3 antibody, but a normal response
to PMA and ionomycin (Fig. 2 B). However, WAS2/2 pe-
ripheral T cells also responded, albeit less than wild-type
cells, to anti-CD3 antibody stimulation combined with PMA
treatment, whereas addition of CD28 could partially re-
store proliferation of these cells (Fig. 2 B, left panel). Anti-
CD3–induced proliferative responses of the WASp-defi-
cient cells were also restored to almost normal levels by the
addition of IL-2 (Fig. 2 B, right panel). To investigate the
basis for this latter finding, anti-CD3–induced production
of IL-2 was also evaluated in the WAS2/2 T cells. As shown
in Fig. 2 E, wild-type T cells secreted only a small amount
of IL-2 after anti-CD3 antibody treatment, but dramati-
cally increased their IL-2 production in conjunction with
anti-CD28 antibody–mediated costimulation. However, in
the WAS2/2 cells, IL-2 production was not only negligible
after anti-CD3 antibody stimulation, but also increased by
much less (50%) in these cells than in wild-type cells after
CD28 costimulation (Fig. 2 E). This defect in the induc-
tion of IL-2 does not reflect impairment of IL-2 secretion,
as an evaluation of IL-2 production based on intracellular
staining of T cells stimulated with anti-CD3/anti-CD28
antibodies in the presence of the secretion blocker Brefel-
din A (59, 60) revealed the numbers of IL-2–staining cells
to be z50% less in the WAS2/2 relative to wild-type cell
cultures (Fig. 2 E). By contrast, in the absence of Brefeldin A,
IL-2 accumulation was not detected in the mutant or wild-
type cells, indicating the IL-2 secretion pathway to be in-
tact in the context of WASp deficiency. Thus, these obser-
vations indicate that WASp effects on TCR signaling are
modulated by costimulatory signals and also suggest that the
T cell proliferative defect conferred by WASp deficiency is
due, at least in part, to a defect in IL-2 production. Taken
together, these data confirm the participation of WASp in
the transduction of activation signals via the TCR and sug-
gest that the effects of WASp on TCR-mediated activation
are most profound in immature T cells and may be tem-
pered by concomitant activation signals delivered via CD28,
IL-2, and possibly other stimulatory receptors. The data
also identify potential functional differences between the T
cells of the WASp-deficient mice studied here and those of
WAS patients in whom anti-CD3–induced proliferative
responses appear to be only partially restored by exogenous
IL-2 (10). While further studies are required to determine
whether this discrepancy reflects the use of transformed
WAS patient cell lines, the current data provide definitive
evidence of a role for WASp in promoting the coupling of
TCR stimulation to T cell activation and to the IL-2 pro-
duction integral to normal T cell mitogenesis.1335 Zhang et al.
In contrast to thymocytes and peripheral T cells, WASp-
deficient splenic B cells showed only a marginal reduction
in response to antigen receptor ligation, a finding that was
not altered by varying the concentrations of anti-Ig anti-
body (Fig. 2 C). As observed in WAS2/2 T cells, this mild
reduction in responsiveness of the WASp-deficient B cells
to mitogenic stimulus appears to be antigen receptor spe-
cific, as these cells proliferated normally in response to LPS,
IL-4 (Fig. 2 C), and the combination of IL-4 with anti-
CD40 antibody (data not shown). Thus, WASp deficiency
appears to be associated with impairment in T cell and to a
much lesser extent, B cell antigen receptor (BCR) signal-
ing. While a defect in BCR signaling was not reported in a
previous study of WASp-deficient mice (45), the current
findings are consistent with data indicating that antigen re-
ceptor–evoked B cell proliferative responses are impaired
Figure 2. Effects of WASp deficiency on antigen receptor–evoked proliferation, IL-2 production, and apoptosis. (A) Freshly isolated T and B lympho-
cytes from the thymi (A), lymph nodes (B), and spleens (C) of 4–8-wk-old WAS2/2 mice (2/2) or age-matched control mice (1/1) were cultured for
48 h with the following stimuli. For thymocytes: anti-CD3 antibody (2 mg/ml), anti-CD3 antibody plus PMA (5 ng/ml), Con A (1 mg/ml), or PMA
and ionomycin (P1I, 250 ng/ml); for lymph node T cells: anti-CD3 antibody (1 mg/ml), anti-CD3 antibody plus anti-CD28 antibody (0.2 mg/ml),
anti-CD3 antibody plus PMA (5 ng/ml), Con A (1 mg/ml), PMA and ionomycin (P1I, 250 ng/ml), or anti-CD3 antibody plus 50 U/ml IL-2; for
splenic cells: IL-4 (2 ng/ml), anti-IgM (1.25 or 5 mg/ml), or LPS (5 mg/ml). Proliferative responses were determined after a 16-h pulse with [3H]thymi-
dine. Values represent means (6SEM) of triplicate cultures and are representative of one of four independent experiments. (D) Flow cytometric analysis
of the expression of the early activation marker CD69 upon treatment of thymocytes with either medium alone (top), anti-CD3 antibody (middle), or
anti-CD3 plus anti-CD28 antibodies (bottom). (E) IL-2 production by WAS2/2 and WAS1/1 thymocytes stimulated for 48 h with anti-CD3 antibody
(2 mg/ml) or anti-CD3 plus anti-CD28 antibody (2 and 0.2 mg/ml, respectively) was evaluated by ELISA of culture supernatants (left panel). Alterna-
tively, lymph node T cells were cultured for 8 h with medium alone or with anti-CD3 (5 mg/ml) or anti-CD3/anti-CD28 (5 mg/ml/4 mg/ml) antibod-
ies, stained with FITC-conjugated anti-CD4 antibody followed by permeabilization and staining with PE-conjugated anti–IL-2 antibody, and analyzed
by flow cytometry (middle panel). Results are expressed as the fold increase in numbers of IL-2–stained CD41 cells in stimulated relative to unstimulated
wild-type cells and represent means (6SEM) of triplicate cultures. Intracellular staining of WAS2/2 and WAS1/1 lymph node cells stimulated with anti-
CD3/anti-CD28 in the presence or absence of Brefeldin A was also evaluated as above (right panel). Values represent means (6SEM) of triplicate cultures.
(F) Thymocytes from WAS2/2 and control WAS1/1 mice were activated by incubation with either medium alone or with plate-bound anti-CD3 an-
tibody (20 mg/well), anti-CD3 plus anti-CD28 antibodies (each 20 mg/well), anti-Fas (0.1 or 5 mg/ml) antibody, or with PMA plus ionomycin (P1I, 10
and 500 ng/ml, respectively) for 24 h, after which the cells were stained with 7-AAD (10 mg/ml) and with FITC-conjugated anti-CD4 and PE-conju-
gated anti-CD8 and analyzed by flow cytometry. Histograms indicate the percentage of viable CD41CD81 cells. Values represent means (6SEM) of
triplicate cultures and are representative of four independent experiments.1336 Regulation of Lymphocyte Function by the Wiskott-Aldrich Syndrome Protein
in patients with classical WAS (9). However, it is currently
unclear whether the divergent effects of WASp deficiency
on TCR versus BCR signaling reflect differences in the
biochemical requirements required for signal delivery by
the respective receptors or the capacity of another effector,
such as N-WASp, to adequately subserve WASp functions
in B, but not T cells.
In view of these data identifying a role for WASp in
coupling antigen receptor engagement to lymphocyte pro-
liferation, the possibility that this protein also modulates
antigen receptor capacity to activate cell death cascades
was also investigated. Specifically, WAS2/2 and wild-type
double-positive thymocytes were cultured for 24 h in the
presence of anti-CD3 antibody alone or combined with
anti-CD28 antibody, and the viability and rate of cellular
apoptosis were then evaluated in CD41CD81 cells by im-
munofluorescence analysis of 7-AAD staining. As shown in
Fig. 2 F, results of this analysis revealed that viability of the
anti-CD3–stimulated WAS2/2 CD41CD81 cells was z35%
greater than that of wild-type cells. This difference was
even more marked in the context of anti-CD3/anti-CD28
stimulation. By contrast, cell viability after anti-Fas anti-
body or PMA/ionomycin treatment was similar in the mu-
tant and wild-type cells. Therefore, these data indicate that
WASp specifically modulates the apoptotic as well as mito-
genic signaling cascades evoked by TCR engagement. At
present, the physiologic significance of these findings re-
mains unclear, although the involvement of WASp in TCR-
mediated apoptosis implies a potential role for this protein
in facilitating negative selection events in the thymus, a pos-
sibility which might be etiologically relevant to the autoim-
mune phenomena frequently expressed by WAS patients (6).
Antigen Receptor–induced Tyrosine Phosphorylation and Acti-
vation of MAPK and SAPK/JNK Appear Normal in WASp-
deficient T Cells. To elucidate the biochemical basis for the
T cell functional defects conferred by WASp deficiency,
WAS2/2 T cells were evaluated with respect to the signal-
ing events elicited by TCR engagement. As indicated by
the antiphosphotyrosine immunoblots shown in Fig. 3, A
and B, the levels of TCR-z, ZAP70, and total cellular pro-
tein tyrosine phosphorylation detected in resting and TCR-
stimulated WAS2/2 thymocytes and peripheral T cells were
Figure 3. Effects of WASp deficiency on TCR signaling. WAS2/2 or WAS1/1 thymocytes or lymph node T cells were stimulated with biotinylated
anti-TCR antibody (10 mg/ml) followed by streptavidin cross-linking (10 mg/ml) for the indicated times. Lysates were prepared as in Materials and Meth-
ods, and the lysate proteins were either (A) resolved over SDS-PAGE and subjected to antiphosphotyrosine immunoblotting analysis; (B) subjected to im-
munoprecipitation with anti–TCR-z (top panel) or anti-ZAP70 (bottom panel) antibodies as well as control rabbit IgG(c) and subsequent sequential im-
munoblotting with antiphosphotyrosine (anti p-Tyr) and anti–TCR-z or anti-ZAP70 antibodies, respectively; (C) immunoprecipitated with anti-ERK1
and anti-ERK2 antibodies as well as control IgG(c), and the immune complexes were evaluated for ability to phosphorylate MBP by SDS-PAGE and au-
toradiography (upper panel) and for amount of ERK1 and ERK2 by immunoblotting analysis (lower panel); or (D) resolved over SDS-PAGE and sub-
jected to sequential immunoblotting analysis with antiphospho-SAPK/JNK (pSAPK/JNK) and anti-SAPK/JNK (JNK1 and JNK2) antibodies. (E) Flow
cytometric analysis of Ca21 influx after stimulation of thymocytes with anti–TCR-a/b antibody. Arrows indicate addition of cross-linking streptavidin.1337 Zhang et al.
essentially identical to those observed in similarly treated
wild-type cells. Along similar lines, TCR-evoked increases
in MAPK activation and in phosphorylation, and presum-
ably activation of SAPK/JNK were comparable (Fig. 3, C
and D). By contrast, the increase in intracellular calcium
levels induced by TCR ligation was less sustained in the
WAS2/2 compared with wild-type cells, with intracellular
calcium concentrations 20 and 25% reduced in the WAS2/2
relative to wild-type cells at the 600- and 700-s time points,
respectively (Fig. 3 E). At present, it is unclear whether this
quantitative difference in intracellular calcium mobilization
observed in wild-type compared with WAS2/2 cells trans-
lates to a sufficiently significant perturbance of other down-
stream signaling events, such as NF-AT translocation to the
nucleus, so as to account for the very significant impair-
ment in TCR-induced IL-2 expression by the mutant cells.
Antigen Receptor–induced Actin Polymerization, Capping, and
Endocytosis Are Defective in WASp-deficient Lymphocytes. As
WASp has also been implicated by many lines of evidence
in the regulation of cytoskeletal architecture, the relevance
of WASp to lymphocyte cytoskeletal rearrangements in-
duced by antigen receptor engagement was also investi-
gated. To this end, WAS2/2 lymphocytes were studied with
respect to the induction of antigen receptor capping, a phe-
nomenon that requires de novo actin polymerization and
microfilament rearrangement. As indicated in Fig. 4 A and
illustrated by the representative micrograph (Fig. 4 B), a
defect in ligand-induced capping was detected in WAS2/2
Figure 4. Analysis of lympho-
cyte cap formation, actin polymer-
ization, and endocytosis and neu-
trophil phagocytosis in WAS2/2
mice. (A) Percentages (6SD) of
WAS1/1 and WAS2/2 thymo-
cytes and splenic B cells showing
antigen receptor clustering after
antigen receptor ligation. Periph-
eral lymph node T cells and
splenic cells from WAS2/2 and
wild-type (1/1) mice were in-
cubated with soluble biotinylated
anti-TCR antibody (1 mg/ml)
or with 1 mg/ml biotinylated
anti–mouse IgD antibody, re-
spectively, followed by FITC-
conjugated streptavidin and then
fixed with 2% paraformaldehyde
as described in Materials and
Methods. Capped cells were then
visualized by fluorescence confo-
cal microscopy, and the percent-
age of capped cells was deter-
mined by scoring cells from 10
microscope fields per sample
(100–200 cells/field). (B) Fluo-
rescence confocal micrograph
(original magnification: 3126)
showing TCR capping of anti-
TCR–stimulated thymocytes (as
above) from WAS2/2 (bottom)
and wild-type (top) mice. (C)
Impairment of actin polymeriza-
tion in WAS2/2 mice. Thymo-
cytes from WAS2/2 and WAS1/1
mice were isolated and stimu-
lated with anti-CD3e antibody
(1 mg/ml) for 30 min on ice, fol-
lowed by cross-linking with a
secondary antibody (outlined
histograms) or alternatively, treated
with the secondary antibody alone (filled histograms). Cells were fixed with 4% paraformaldehyde, and F-actin content was quantitated by flow cytomet-
ric analysis of FITC-phalloidin–stained cells. One result representative of three independent experiments is shown. (D) TCR internalization in WAS2/2
T cells. Lymph node T cells from WAS2/2 and wild-type mice were incubated for 30 min on ice with anti-CD3 antibody (1 mg/ml) and then washed
and incubated for an additional 30 min on ice with biotinylated goat anti–hamster antibody (2 mg/ml). Cells were then warmed to 378C, and aliquots
were removed at 5 and 60 min, mixed with 0.1% NaN3 on ice, and stained with FITC-conjugated streptavidin. Cells were then fixed for 15 min in 4%
paraformaldehyde, and surface TCR expression was analyzed by flow cytometry. (E) Phagocytic activity of bone marrow neutrophils from WAS2/2
mice. Neutrophils were purified from WAS2/2 and wild-type bone marrow as described in Materials and Methods and then incubated for 5 min at 378C
with opsonized zymosan and lucifer yellow. Cells were then washed, and the percentage of lucifer yellow–containing phagosomes was evaluated by flu-
orescence microscopy. The percent phagocytosis was calculated from the total number of cells with lucifer yellow–stained phagosomes relative to the to-
tal number of cells in six to eight high-power fields. Values represent the mean 6 SEM of five independent experiments.1338 Regulation of Lymphocyte Function by the Wiskott-Aldrich Syndrome Protein
thymocytes, the number of these cells showing T cell anti-
gen receptor clustering to be z40% less than that of wild-
type thymocytes. As is consistent with a defect, albeit mild
in BCR-induced proliferation, anti-Ig–mediated capping
of the BCR was also impaired in the context of WASp
deficiency. In addition, immunofluorescence analysis of
anti-CD3–treated phalloidin-labeled WAS2/2 thymocytes,
an assay that selectively detects expression of polymerized
F-actin, revealed that antigen receptor–mediated actin po-
lymerization was markedly reduced in WAS2/2 thymo-
cytes (Fig. 4 C) and lymph node T cells (data not shown).
Together, these data demonstrate a requirement for WASp
in the regulation of cytoskeletal rearrangement in response
to antigen receptor engagement.
In addition to patch and cap formation, internalization of
antigen receptors after their engagement appears to require
cytoskeletal rearrangement, as endocytosis of these recep-
tors is abrogated by cytoskeleton-disrupting agents such as
dihydrocytochalasin B (61). In view of this observation, to-
gether with data from our lab (Siminovitch, K., unpublished
observations) and another (62) revealing the capacity of
WASp and the Las17/Beel yeast WASp homologue, re-
spectively, to interact with proteins implicated in endocyto-
sis, the possibility that WASp plays a role in ligand-trig-
gered TCR endocytosis was investigated by assaying the
levels of biotinylated TCR present on WAS2/2 T cells at
varying times after cell stimulation. As illustrated in Fig. 4 C,
the results of this analysis revealed the rate of TCR endo-
cytosis to be markedly reduced in the context of WASp
deficiency, with 50% of the receptors internalized in wild-
type cells, but only 10% internalized in WAS2/2 cells at 1 h
after stimulation. Therefore, these results suggest the in-
volvement of WASp in the process of receptor endocytosis.
At present, the level at which the endocytic pathway is dis-
rupted by WASp deficiency remains unclear. However, this
defect may also impact on the properties of nonlymphoid
cells, as opsonized zymosan particle internalization was also
found to be significantly reduced in WAS2/2 compared with
wild-type neutrophils (Fig. 4 E). Together, these data raise
the possibility that the altered endocytosis of the TCR
and/or other receptors and consequent changes in levels of
surface receptor expression impact on a broad range of im-
mune cellular functions, including not only cell activation, but
also maintenance of cell polarity, antigen presentation, and/
or the uptake of extracellular nutrients and microorganisms.
In summary, the current data reveal that transduction of
TCR-evoked proliferation, apoptosis, and actin polymer-
ization–inducing signals are impaired in WAS2/2 T cells.
WASp deficiency also engenders a defect in thymocyte
maturation, by impairment of the progression of CD42
CD82 progenitors from the CD442CD251 to a CD442
CD252 stage. This developmental defect may reflect di-
minished signaling capacity of the pre-TCR in the absence
of WASp, as has been previously proposed in relation to
the similar, albeit more severe, maturational defect detected
in Lck-deficient thymocytes (53). Similarly, the reduction in
peripheral T cell numbers conferred by WASp deficiency
may reflect not only impaired thymopoiesis, but also dimin-
ished proliferative/expansion potential consequent to defec-
tive transduction of TCR mitogenic signals. As is consistent
with the immunologic abnormalities described in WAS pa-
tients, the early stages of B cell ontogeny appear intact and
BCR-induced proliferation is only modestly diminished in
the context of WASp deficiency. However, the reduction in
splenic B cell numbers and in capping capacity of stimulated
antigen receptors on WAS2/2 B cells implies that the mod-
est diminution in antigen receptor–evoked B cell prolifera-
tion is physiologically relevant and may engender impaired
expansion of B cells within the peripheral compartment.
Despite the plethora of functional defects detected in
WAS2/2 T cells and thymocytes, many of the biochemical
events involved in signal relay through the TCR (such as
tyrosine phosphorylation and MAPK and SAPK/JNK acti-
vation) remain intact in these cells. In this context, the
WAS2/2 cells are strikingly similar to the lymphoid cells of
mice genetically rendered deficient for Vav (63–65), a gua-
nine nucleotide exchange factor for the Rho family of GTP-
ases (66, 67). Although the effect of Vav deficiency on B
cell ontogeny and function is more prominent than that of
WASp deficiency, Vav2/2 mice manifest defects in T cell
maturation, TCR-evoked proliferation, cytokine produc-
tion, and actin polymerization that closely resemble those
observed in the WAS2/2 mice. In addition, as with WAS2/2
T cells, Vav2/2 T cells show little or no abnormalities with
respect to the early activation events induced by TCR liga-
tion. At present, the biochemical basis whereby both the
structural (receptor clustering and actin polymerization)
and physiologic (proliferation and cytokine production) se-
quelae of TCR ligation are disrupted by WASp or Vav de-
ficiency remains unclear. However, a relationship between
these facets of T cell activation has become increasingly
well recognized and is strongly supported by recent data
indicating a pivotal role for cytoskeletal rearrangement in
reorienting the T cell–APC interface so as to create a
framework for the incorporation of signaling molecules
into supramolecular activation clusters (SMACs) that am-
plify signal delivery (68, 69). Taken together with the T cell
defects observed in WAS2/2 mice, these observations sug-
gest that while TCR activation signals can be initiated in
the absence of cytoskeletal-driven events such as receptor
clustering, signal delivery in this context is insufficient to
achieve optimal activation and cytokine production. Thus,
by virtue of its capacity to interact with both cdc42 and the
Arp2/3 complex, WASp may act to promote the spatial re-
arrangements required for SMAC formation and thereby
facilitate the juxtaposition of activated antigen receptors
and signaling molecules that is required for efficient trans-
duction of activation signals. Accordingly, the defective ac-
tin polymerization and TCR clustering engendered by
WASp deficiency would predictably translate to signaling
of insufficient amplitude and/or duration for optimal acti-
vation and cytokine production. This hypothesis is supported
by preliminary data revealing that T cell microtubule orga-
nizing center (MTOC) polarization toward the T cell–
APC contact site is reduced in stimulated WAS2/2 T cells
(Burkhardt, J., and K. Siminovitch, data not shown) and, if1339 Zhang et al.
correct, might explain the disparate effects of WASp defi-
ciency on B cell versus T cell activation, the latter of which
appears more highly dependent on proper actin filament as-
sembly (70, 71). In view of data indicating CD28–B7 in-
teraction to be both necessary and sufficient for inducing
movement of the cortical actin cytoskeleton toward the
TCR–ligand interface (68), the capacity of CD28 costimu-
lation to partially normalize TCR-evoked proliferative re-
sponses of WAS2/2 T cells suggests that WASp effects on
cytoskeletal rearrangement may be particularly important
for the propagation of TCR-initiated signals evoked in the
absence of costimulatory signal. The capacity of WASp to
interact with Nck may also be of some relevance to WASp
effects on TCR signaling, as the Nck adaptor protein has
been shown to promote TCR-mediated NF-AT activation
by virtue of an interaction with the Pak1 serine/threonine
kinase (40). As Pak1, like WASp, appears to act downstream
of cdc42 activation in a JNK-independent fashion, these
observations suggest that WASp effects on TCR-evoked
IL-2 production may reflect not only WASp modulation of
upstream cytoskeletal-mediated TCR rearrangements, but
also WASp interactions with both activated cdc42 and Nck.
While these hypotheses require further investigation, the
current data indicate that mice with WASp-deficient lym-
phoid cells provide a valuable system for dissecting out the
complex structural and biochemical properties of WASp
and delineating the molecular events that couple antigen
receptor stimulation to cytoskeletal rearrangement and
lymphocyte activation.
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